Sign In
Buy TWST
$72.33
+2.18 (+3.11%)
At Close: Jun 03, 2026
Twist Bioscience Corporation (TWST) Q1 2025 Earnings Call Transcript
10:55am, Monday, 03'rd Feb 2025
Twist Bioscience Corporation (NASDAQ:TWST ) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust
Twist Bioscience (TWST) Reports Q1 Loss, Tops Revenue Estimates
09:25am, Monday, 03'rd Feb 2025
Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago.
Twist Bioscience Announces Fiscal 2025 First Quarter Financial Results
07:15am, Monday, 03'rd Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Gene Synthesis Market Size to Surpass USD 9.54 Billion by 2033 | Straits Research
10:35am, Thursday, 23'rd Jan 2025
The global gene synthesis market size was valued at USD 2.20 billion in 2024 and is projected to reach from USD 2.55 billion in 2025 to USD 9.54 billion by 2033, growing at a CAGR of 15.8% duri
All You Need to Know About Twist Bioscience (TWST) Rating Upgrade to Buy
01:00pm, Friday, 27'th Dec 2024
Twist Bioscience (TWST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Twist Bioscience (TWST) Surges 9.9%: Is This an Indication of Further Gains?
09:51am, Monday, 23'rd Dec 2024
Twist Bioscience (TWST) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near
Twist Bioscience to Present at 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Thursday, 19'th Dec 2024
SOUTH SAN FRANCISCO--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announce
Twist Bioscience (TWST) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:57am, Monday, 16'th Dec 2024
After losing some value lately, a hammer chart pattern has been formed for Twist Bioscience (TWST), indicating that the stock has found support. This, combined with an upward trend in earnings estimat
Twist Bioscience: Path To Profitability Beginning To Take Shape
09:55am, Friday, 29'th Nov 2024
Twist Bioscience's SynBio and NGS segments continue to generate strong growth, despite macro challenges. The prospects of the biopharma segment are uncertain, highlighted by the sale of milestones and
Twist Bioscience: A Post-Earnings Assessment
03:16pm, Monday, 18'th Nov 2024
Twist Biosciences just posted a solid Q4, which had the stock rising in trading Monday. However, despite impressive sales growth, Twist Biosciences remains unprofitable, with projected losses for seve
Twist Bioscience's Q4 Earnings And Q1 Guidance Surpass Expectations, Stock Jumps
12:17pm, Monday, 18'th Nov 2024
On Monday, Twist Bioscience Corporation TWST reported a fourth-quarter loss per share of 59 cents, beating the consensus loss of 70 cents.
Twist Bioscience Corporation (TWST) Q4 2024 Earnings Call Transcript
11:31am, Monday, 18'th Nov 2024
Twist Bioscience Corporation (NASDAQ:TWST ) Q4 2024 Earnings Conference Call November 18, 2024 8:00 AM ET Company Participants Angela Bitting - SVP, Corporate Affairs Emily Leproust - CEO and Co-Found
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
09:25am, Monday, 18'th Nov 2024
Twist Bioscience (TWST) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $0.81 per share a year ago.
Twist Bioscience Announces Fiscal 2024 Fourth Quarter and Full Year Financial Results
07:15am, Monday, 18'th Nov 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today
Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'
05:14am, Friday, 08'th Nov 2024
Since I last covered it, Twist Bioscience has made significant strides. They have secured new partnerships, launched innovative products, and secured strategic financial agreements. TWST's valuation m
